Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 82.5% in February

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 2,466,525 shares, a growth of 82.5% from the January 29th total of 1,351,651 shares. Currently, 13.7% of the company’s stock are sold short. Based on an average trading volume of 853,907 shares, the short-interest ratio is presently 2.9 days. Based on an average trading volume of 853,907 shares, the short-interest ratio is presently 2.9 days. Currently, 13.7% of the company’s stock are sold short.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI traded up $0.06 during mid-day trading on Friday, hitting $9.41. The stock had a trading volume of 529,971 shares, compared to its average volume of 685,656. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $10.99. The stock has a market cap of $172.58 million, a price-to-earnings ratio of -0.57 and a beta of 0.21. The company’s 50 day simple moving average is $7.59 and its 200 day simple moving average is $6.64.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to the consensus estimate of $33.16 million. As a group, equities analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the second quarter valued at $45,000. XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $56,000. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics in the 4th quarter valued at about $74,000. Tudor Investment Corp ET AL bought a new position in Karyopharm Therapeutics in the 4th quarter valued at about $95,000. Finally, Persistent Asset Partners Ltd bought a new position in Karyopharm Therapeutics in the 4th quarter valued at about $135,000. 66.44% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KPTI has been the topic of a number of research reports. Royal Bank Of Canada cut their price objective on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Cantor Fitzgerald assumed coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.83.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.